BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
Terminated
- Conditions
- Non-valvular Atrial Fibrillation
- Interventions
- Drug: Rivaroxaban (Xarelto, BAY59-7939)Drug: Apixaban (Eliquis)Drug: Dabigatran etexilate (Pradaxa)Drug: Warfarin (Marevan)
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70000
- Registration Number
- NCT03715725
- Locations
- 🇳🇴
Many Locations, Multiple Locations, Norway
Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.
Completed
- Conditions
- Macular Degeneration
- Interventions
- Drug: Ivt. Aflibercept (Eylea, BAY86-5321)
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 554
- Registration Number
- NCT03714308
- Locations
- 🇩🇪
Many locations, Multiple Locations, Germany
Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- Drug: Nifurtimox (Lampit, BAYA2502)_TestDrug: Nifurtimox (Lampit, BAYA2502)_Reference
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT03708133
- Locations
- 🇦🇷
FP Clinical Pharma, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina
Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.
Phase 1
Completed
- Conditions
- Cerebrovascular Circulation
- Interventions
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT03704519
- Locations
- 🇬🇧
Centre for Neuroimaging Sciences, King's College, London, United Kingdom
Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
Phase 3
Withdrawn
- Conditions
- Uterine Fibroids
- Interventions
- Drug: PlaceboDrug: Vilaprisan (BAY1002670)
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Bayer
- Registration Number
- NCT03699176
- Locations
- 🇯🇵
Ena Odori Clinic, Sapporo, Hokkaido, Japan
🇯🇵Asahi clinic, Takamatsu, Kagawa, Japan
🇯🇵Matsudo City General Hospital, Matsudo, Chiba, Japan
Accessibility to New Drugs Versus SOC in Sweden
Completed
- Conditions
- Anticoagulation
- Interventions
- Drug: Standard of care (Warfarin)
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 68056
- Registration Number
- NCT03684395
Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)
Not Applicable
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- Device: BAY987534
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 42
- Registration Number
- NCT03672383
- Locations
- 🇩🇪
proDerm, Hamburg, Germany
Occurrence and Trend of Pregnancies Growing Outside the Womb (Ectopic Pregnancy) 2009-2018. A Study on a Defined Group of Persons
Completed
- Conditions
- Pregnancy, Ectopic
- Interventions
- Other: No intervention
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3922877
- Registration Number
- NCT03670784
- Locations
- 🇺🇸
Kaiser Permanente, San Francisco, California, United States
Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
Phase 1
Completed
- Conditions
- Advanced Solid TumorHead and Neck Squamous Cell Carcinoma
- Interventions
- Drug: Bapotulimab (BAY1905254)Drug: Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 60
- Registration Number
- NCT03666273
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics | START San Antonio, San Antonio, Texas, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Copanlisib (Aliqopa, BAY80-6946)Drug: Metformin
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13
- Registration Number
- NCT03655301
- Locations
- 🇺🇸
Pharmaceutical Product Development (PPD), LLC, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath